🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Super🌟Tanya Jindal CWRU School of Medicine continues to impress w important analyses from Unite study. Robust ORR and DCR with EV/P after prior ICI in #mUC presented at @asco #GU25 UCSF Helen Diller Family Comprehensive Cancer Ctr Petros Grivas Amanda Nizam, MD Shilpa Gupta Omar Alhalabi, MD Abhishek Tripathi Jason Brown UroToday.com Uromigos

So important that this dataset from Tom Powles Uromigos Barts Experimental Cancer Medicine Centre, Petros Grivas Fred Hutchinson Cancer Center University of Washington, et al is out there for our detailed evaluation. The role of #sacituzumab in #BladderCancer appears to still be hotly debated, as discussion from our recent #AUC3 meeting

HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains Vadim Koshkin MD doi.org/10.1093/oncolo…

SHR-A2102 Nectin-4/Topo-1 ADC with 38% RR & 5.5 mnth PFS in pretreated (~50% prior ADCs) urothelial cancer (n=81). Adverse events focus on top-1 tox (haem). This is the 1st Nectin/topo1 combo & looks more like EV than SG activity-the target maybe more important than the payload.

Fantastic start at #MatosGU25 on liquid biopsies! Alan Tan discussed tumor informed vs agnostic assays! Citing data from Tom Powles & discussion by Bogdana Schmidt MD, MPH Matt Galsky 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Dr. Luis E. Raez The Medical Educator Consortium David McConkey Arnab Basu Rafee Talukder Vadim Koshkin MD Mehmet Asim Bilen,MD

⭐️Outstanding Keynote talk by Dr. Benjamin Maughan GU Cancer Research Program @HuntsmanCancer on Prostate inhibitors in earlier stages of prostate cancer. Great discussion of upcoming studies in mHSPC and localized prostate cancer with PARP inhibitors. Benjamin L Maughan Petros Grivas UroToday.com ONCO BRUNO

⭐️Dr. Arpita Desai UCSF Helen Diller Family Comprehensive Cancer Ctr kicks off day 2 with a stellar discussion of molecular imaging 2025 updates in RCC. Arpita Desai Petros Grivas #MatosGU25 Stephanie Berg Tanya Dorff Yousef Zakharia Hans Hammers Chad Tang, MD @Catherine_Fahey Arpita Desai OncLive.com UroToday.com

Great wrap of #MATOSGU25 with case-based bladder ca, nice debate. This meeting exceeded my expectation ! Petros Grivas 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Edgardo Santos, MD, FACP, FASCO Dr. Luis E. Raez

Exciting 177Lu-PSMA-617 has been approved by the FDA for use prior to chemotherapy based on the PSMAfore results. Perfect timing, during day 1 of the PSMA and Beyond Conference! bit.ly/42lfdlz

Introducing the #UromigosScore for urothelial cancer in perioperative, front-line advanced and EVP-refractory disease. Global experts rank treatment preferences and mean results are presented. Listen to full details on the scoring system and results here: spotifycreators-web.app.link/e/JCTzaAb46Rb

The Uromigos are Live at #GUTrends25 Tom Powles & Brian Rini, MD discuss the #UromigosScore 🧮 Progression after 2L This first started in Urothelial cancer, where 18 experts were asked🌐on how they would score a given treatment in a given treatment scenario, with a score range of

FDA approves Durva in neoadjuvant chemotherapy for bladder cancer - Practice changing for our patients. Petros Grivas Shilpa Gupta

1/3 #GUTrends25 explore new ADCs in heavily pretreated UC. Targets= HER2/NECTIN4/TROP2/EGFR/HER3. Studies are heterogeneous (DDXD ~70% prior ADC) & numbers small. 40% ORR for EV = benchmark. Both MMAE and TOPO1 have drugs with ORRs >40%. TROP2 target appears modest for ORR

Part 2 of our series on ADCs with Ignacio Duran explores novel agents and novel targets. spotifycreators-web.app.link/e/pL6ADjFTeSb

📺 Watch Vadim Koshkin MD give a recap of his PSMA and Beyond Conference presentation on opportunities for radioligand therapy in #bladdercancer: buff.ly/9O7kUNz 🔎 The first segment of his presentation focuses on fibroblast activation proteins (FAP)-targeted theranostics,

Our most recent episode of Oncology Unplugged is live! Listen 🎧 to 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 of Norton Healthcare IT and Vadim Koshkin MD of UCSF Helen Diller Family Comprehensive Cancer Ctr explore the clinical implications of the phase 3 NIAGARA trial for patients with resectable bladder cancer. Full episode here🎙️: onclive.com/view/bladder-s…

👉 Vadim Koshkin MD and Amanda Nizam, MD break down recent research on #pembrolizumab retreatment in patients with advanced or metastatic #urothelial carcinoma who responded to first-course pembrolizumab-based therapy: buff.ly/V1yhYUL 🔎 Watch to learn more about the

#ASCO25 abstracts titlkes are out!!!!! meetings.asco.org/meetings/2025-… Much Looking forward to seeing the exciting new data in GU tumors!!!! See you all in Chicago!!!! ASCO The ASCO Post Toni Choueiri, MD Tom Powles Shilpa Gupta Michiel vd Heijden Robert Motzer MD GUARD Consortium

Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma. Co-authored by Vadim Koshkin MD brnw.ch/21wSdzb

Big news in bladder cancer. R3 (n=480) of Disitimab Vedotin(HER2ADC) + Tori (PD1) vs chemo, hitting PFS + OS in 1st line irrespective of HER2 . “This reshapes the global treatment landscape of urothelial carcinoma with the Chinese regimen,”said Dr. Jun Guo remegen.com/index.php?v=sh…